Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20457102 | 0.81 | LMNA (0.37) | HSP90AA1LMNAMAPTNR4A2L3MBTL1 | |
| SCHEMBL31234990 | 0.80 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1NOTUMTSHRKMT2A | |
| SCHEMBL24615642 | 0.80 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1NOTUMTSHRKMT2A | |
| SCHEMBL22655924 | 0.71 | SMN1; SMN2 (0.46) | HSP90AA1HSP90AB1LMNANOTUMHTT | |
| SCHEMBL29344558 | 0.70 | TSHR (0.35) | LMNANOTUMTSHR | |
| SCHEMBL11985884 | 0.70 | LMNA (0.42) | HSP90AA1LMNAMAPTHTTNR4A2 | |
| SCHEMBL28251597 | 0.70 | LMNA (0.42) | HSP90AA1LMNAMAPTHTTNR4A2 | |
| SCHEMBL12597876 | 0.68 | ALDH1A1 (0.38) | LMNAMAPTHTTL3MBTL1GAA | |
| SCHEMBL14853385 | 0.67 | LMNA (0.39) | HSP90AA1LMNAMAPTNR4A2L3MBTL1 | |
| SCHEMBL24529687 | 0.67 | MAPT (0.46) | HSP90AA1LMNAMAPTNR4A2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | HSP90AA1 1614/4885HSP90AB1 1306/4885LMNA 4027/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | HSP90AA1 4150/4885HSP90AB1 4121/4885LMNA 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.